Latest Breaking News On - அறிக்கைகள் இது - Page 5 : comparemela.com

Share this article DRESDEN, Germany, March 2, 2021 /PRNewswire/  GEMoaB, a biopharmaceutical company focused on the development of next-generation immunotherapies for hard-to-treat cancers, today announced the publication of clinical data obtained from the ongoing Phase I study of their rapidly switchable UniCAR platform lead asset, UniCAR-T-CD123, in relapsed/refractory acute myeloid leukemia (rrAML), in the journal Blood . The interim data of UniCAR-T-CD123 in rrAML, published online ahead of print as a letter in Blood (Wermke et al. 2021, https://doi.org/10.1182/blood.2020009759), demonstrate that UniCAR-T-CD123 in rrAML is well-tolerated with rapid recovery of hematopoiesis and encouraging early efficacy. The Blood publication nicely underpins the clinical advantages of our rapidly switchable UniCAR platform, which have also been recently presented at the 3

Prnewswire gemoaJana fiebigerMichael pehlBristol myers squibbGerhard ehningerGerman federal ministry for educationCell meetingChief medical officerAcute leukemiaGerman federal ministryAffinity tailored adaptorStatements thisமைக்கேல் பெல்பிரிஸ்டல் மைஸ் ஸ்க்விப்ப்ஜெர்மன் கூட்டாட்சியின் அமைச்சகம் க்கு கல்விசெல் சந்தித்தல்